SCHEMBL5136644

SCHEMBL5136644

CCCCN(Cc1c(F)cccc1F)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1C

nearest known ligand 0.40

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.40
CRHR1 P34998 3/20 0.38
HDAC1 Q13547 1/20 0.37
ATP4A P20648 3/20 0.36
ATP4B P51164 3/20 0.36
TSHR P16473 3/20 0.36
HSD11B1 P28845 2/20 0.36
NR1H3 Q13133 1/20 0.35
C5AR1 P21730 1/20 0.35
ALDH1A1 P00352 2/20 0.34
CYP3A4 P08684 2/20 0.34
HPGD P15428 2/20 0.34
HSD17B10 Q99714 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137873 0.89 KDM4E (0.38) KDM4ECRHR1HDAC1ATP4AATP4B
SCHEMBL5074878 0.89 TSHR (0.42) KDM4ECRHR1HDAC1ATP4AATP4B
SCHEMBL5134701 0.89 KDM4E (0.39) KDM4ECRHR1HDAC1ATP4AATP4B
SCHEMBL5135270 0.88 KDM4E (0.39) KDM4ECRHR1HDAC1ATP4AATP4B
SCHEMBL5135911 0.86 TSHR (0.39) KDM4ECRHR1ATP4AATP4BTSHR
SCHEMBL5135045 0.84 C5AR1 (0.38) KDM4ECRHR1TSHRC5AR1ALDH1A1
SCHEMBL5137109 0.83 P2RX7 (0.39) CRHR1HDAC1ATP4AATP4BC5AR1
SCHEMBL5072419 0.83 CRHR1 (0.36) KDM4ECRHR1TSHRC5AR1ALDH1A1
SCHEMBL5134752 0.83 C5AR1 (0.39) KDM4ECRHR1TSHRC5AR1ALDH1A1
SCHEMBL5136139 0.82 TSHR (0.37) KDM4ECRHR1TSHRC5AR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed